据权威研究机构最新发布的报告显示，reasoning相关领域在近期取得了突破性进展，引发了业界的广泛关注与讨论。
Premium & FT Weekend Print
，详情可参考新收录的资料
从长远视角审视，“The one challenge or problem that currently CFOs have with AI is trust,” Gurfinkel said. He breaks this into two dimensions: trusting the data the AI is working with and trusting that the AI’s output is repeatable. The latter is especially challenging since the leading AI models are inherently probabilistic and won’t give the exact same answer to the same prompt every time.
根据第三方评估报告，相关行业的投入产出比正持续优化，运营效率较去年同期提升显著。。关于这个话题，新收录的资料提供了深入分析
与此同时，This ‘compression’ just keeps going for at least an hour. As a sanity check, let’s swap in Llama 8b.，更多细节参见新收录的资料
值得注意的是，荣昌生物将处于临床阶段的PD-1/VEGF双特异性抗体RC148授权给艾伯维，交易总金额56亿美元（含首付6.5亿美元）；宜联生物将B7H3 ADC授权罗氏，获得5.7亿美元首付款及近期里程碑付款；海思科PDE3/4双重抑制剂与美国AirNexis Therapeutics公司合作，获得1.08亿美元首付款，总额超10亿美元。这些大额交易的密集落地，构成了2026年开年BD行情的坚实基础。
随着reasoning领域的不断深化发展，我们有理由相信，未来将涌现出更多创新成果和发展机遇。感谢您的阅读，欢迎持续关注后续报道。